Third Wave of the EVAL-PLH (POLYhandicap) Cohort: New Eyes

Study acronym: EVAL-POLYNE
StatusRecruiting
PhaseNot specified
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 2 years later Sep 1, 2026 → Sep 1, 2028
See other at-risk trials from Assistance Publique Hopitaux De Marseille

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary and study completion pushed from Sep 1, 2026 to Sep 1, 2028 Show 6 more changesShow less
    • Recruitment opened
    • Start date changed from estimate of Mar 1, 2025 to Oct 13, 2025
    • Primary endpoints: details revised at 1 of 1 entry
    • Eligibility criteria expanded, about 18 words
    • Secondary endpoints: details revised at 2 of 4 entries
    • Site details revised at 6 of 6 sites
  2. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
The general objective of the EVAL-PolyNE project is to improve the representativeness of the EVAL-PLH cohort by broadening participation in the John Bost Foundation, due to its geographical particularity and its private valence.
Trial Details
NCT Number NCT06811441
Lead Sponsor Assistance Publique Hopitaux De Marseille
Conditions
(from sponsor)		 Polyhandicap
Enrollment 1,102 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov